Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Primary Hyperoxaluria
Primary Hyperoxaluria
Dicerna can’t catch up with Alnylam
EP Vantage
Mon, 08/9/21 - 10:50 am
Dicerna
Primary Hyperoxaluria
Alnylam
nedosiran
Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win
Endpoints
Thu, 08/5/21 - 11:24 pm
Dicerna
RNAi
Primary Hyperoxaluria
clinical trials
Alnylam provides long-term look at Oxlumo, aiming to further carve out stake in PH1 market
Endpoints
Tue, 05/4/21 - 10:38 am
Alnylam
Oxlumo
Primary Hyperoxaluria
clinical trials
Biotech’s important clinical data readouts
EP Vantage
Fri, 03/26/21 - 10:35 am
biotech
Scholar Rock
apitegromab
spinal muscular atrophy
Alnylam
vutrisiran
Dicerna
nedosiran
Primary Hyperoxaluria
FDA
FDA approves Alnylam's first-ever drug for rare kidney disease
Bizjournals
Tue, 11/24/20 - 10:41 am
Alnylam
FDA
kidney disease
Primary Hyperoxaluria
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
BioSpace
Thu, 10/1/20 - 11:28 am
Alnylam
lumasiran
clinical trials
Primary Hyperoxaluria
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Wed, 04/8/20 - 10:51 am
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Sat, 10/19/19 - 01:36 pm
Novartis
fevipiprant
severe asthma
Alnylam
lumasiran
Primary Hyperoxaluria
Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1
Pharmaceutical Business Review
Tue, 07/16/19 - 11:04 pm
Dicerna Pharmaceuticals
FDA
breakthrough therapy
Primary Hyperoxaluria
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
CP Wire
Thu, 05/3/18 - 11:34 am
Alnylam
lumasiran
Primary Hyperoxaluria
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Thu, 05/3/18 - 11:12 am
Alnylam
lumasiran
Primary Hyperoxaluria